Atlas Private Wealth Advisors’s Altimmune ALT Stock Holding History

Atlas Private Wealth Advisors’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-300	Closed	-$3K	–	170
2021 Q3	$3K	Hold	300	–	–	﹤0.01%	613
2021 Q2	$3K	Hold	300	–	–	﹤0.01%	618
2021 Q1	$4K	Hold	300	–	–	﹤0.01%	636
2020 Q4	$3K	Hold	300	–	–	﹤0.01%	575
2020 Q3	$4K	Sell	300 -373	-55%	-$7.46K	﹤0.01%	488
2020 Q2	$7K	Buy	+673	New	+$3.7K	0.01%	454

Other funds holding ALT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Atlas Private Wealth Advisors's ALT Position: Q4 2021 in Review

Atlas Private Wealth Advisors sold out of Altimmune (ALT) in Q4 2021, closing a stake of 300 shares — an estimated $3K sold.

Atlas Private Wealth Advisors first reported a position in ALT in Q2 2020 and held it in 6 quarters. The position peaked at $7K in Q2 2020. 102 funds tracked by Wall St. Rank hold ALT as of Q4 2021.

Atlas Private Wealth Advisors reported no remaining Altimmune position as of Q4 2021 after selling out during the quarter.
Atlas Private Wealth Advisors sold 300 Altimmune shares in Q4 2021, an estimated $3K.
Atlas Private Wealth Advisors first reported a position in Altimmune in Q2 2020 and held it in 6 quarters.
Atlas Private Wealth Advisors's Altimmune position peaked at $7K in Q2 2020.
102 funds tracked by Wall St. Rank held Altimmune as of Q4 2021.

Based on Atlas Private Wealth Advisors's 13F filing for Q4 2021, filed 21 Apr 2022.